The residents of the Mount Sinai Internal Medicine Residency Program are truly what make our program shine. Our trainees come from all over, representing many of the best medical schools throughout the United States and the world. Prior to residency, many already are leaders in biotechnology, translational research, genomics, primary care and public health.
The Internal Medicine Residency Program at Mount Sinai is designed to foster a team approach to patient care and learning. An essential component of that is creating an environment of friendship, camaraderie and well-being among residents and between residents and faculty.
Our newest intern class, for example, has distinguished themselves in many impressive ways:
• An MD /MPH from Case Western Reserve University School of Medicine who has spent five years designing and implementing community and provider interventions in Cleveland for the promotion of pre-exposure prophylaxis for HIV infection in high-risk populations;
• An MD/PhD from the Icahn School of Medicine at Mount Sinai who worked with Ming-Ming Zhao on the detailed study of a novel epigenetic pathway in embryonic stem cells with significant implications for current epigenetic drugs undergoing clinical trials in myeloma and leukemia and the role of epigenetics during T cell polarization in a mouse model of colitis;
• An MD from the Albert Einstein School of Medicine who has served as an innovative leader in student medical education as a senator for medical education on the Einstein Student Council, a student representative to the Association of American Medical Colleges (AAMC), and as a leading member of the Einstein Curriculum Design Executive Committee (CDEC), charged with creating the vision and structure for a new curriculum;
• An MD/PhD from NYU whose graduate work focused on the origin of alternatively activated or M2 macrophages, a subset of cells involved in the resolution of inflammation, and the regulatory signals that modulate M2 polarization during plaque regression in mouse models of atherosclerotic disease;
• An MD from Georgetown who has worked for a Dutch health-care technology startup focused on setting up expanded access/compassionate use programs to provide access to investigational therapeutics for terminally ill patients;
• An MD from the University of Maryland who spent two years in the Experimental Transplantation and Immunology Branch of the National Cancer Institute on projects focused on the genetic modification of the T-cell receptors (TCRs) of patients with recurrent/refractory epithelial malignancies to target their disease.